GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parmax Pharma Ltd (BOM:540359) » Definitions » Net Income From Continuing Operations

Parmax Pharma (BOM:540359) Net Income From Continuing Operations : ₹-20.8 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Parmax Pharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Parmax Pharma's net income from continuing operations for the three months ended in Dec. 2024 was ₹-3.9 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was ₹-20.8 Mil.

Parmax Pharma Net Income From Continuing Operations Historical Data

The historical data trend for Parmax Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parmax Pharma Net Income From Continuing Operations Chart

Parmax Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.31 12.08 3.03 0.46 -56.56

Parmax Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.53 -14.79 0.12 -2.17 -3.95

Parmax Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-20.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parmax Pharma Ltd (BOM:540359) » Definitions » Net Income From Continuing Operations
Comparable Companies
NSE:SAROJA BOM:524768 BOM:531521 BOM:531210 BOM:531015 BOM:523620 BOM:524752 BOM:524400 BOM:530057 BOM:531762 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Website
https://www.parmaxpharma.com
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.

Parmax Pharma Headlines

No Headlines